VIR - Vir Biotechnology GAAP EPS of $3.92 beats by $1.29 revenue of $812.7M beats by $189.8M

Vir Biotechnology press release (NASDAQ:VIR): Q4 GAAP EPS of $3.92 beats by $1.29. Revenue of $812.7M (+46876.9% Y/Y) beats by $189.8M. Cash, Cash Equivalents and Investments: As of December 31, 2021, excluding restricted cash, the Company had approximately $909.5M in cash, cash equivalents, and investments. Excluding restricted cash and its equity investment in Brii Biosciences, the Company had approximately $766.4 million in cash, cash equivalents and investments.

For further details see:

Vir Biotechnology GAAP EPS of $3.92 beats by $1.29, revenue of $812.7M beats by $189.8M